Russia Launches Free Cancer Vaccine
Russia Launches Free Cancer Vaccine – Russia has officially launched EnteroMix, a new mRNA-based cancer vaccine, which it will provide free of charge to patients as it begins clinical deployment.
The vaccine, initially targeted at colorectal cancer, represents a significant milestone in the global fight against cancer and the advancement of personalized medicine.
Developed jointly by the National Medical Research Radiological Center under the Russian Ministry of Health and the Engelhardt Institute of Molecular Biology (EIMB) of the Russian Academy of Sciences (RAS), EnteroMix utilizes messenger RNA (mRNA) technology to train the immune system to recognize and attack cancerous cells.
According to Russian authorities, preclinical and early clinical trials of EnteroMix have shown tumor growth reduction of up to 80%, with no serious side effects reported.
In some clinical settings, the vaccine demonstrated 100% efficacy and safety, particularly in reducing tumor size and preventing further progression.
“This vaccine is designed to be fully personalized,” said Veronika Skvortsova, head of the Federal Medical Biological Agency (FMBA).
“It is tailored to each patient’s individual RNA profile, enhancing its effectiveness and compatibility.”
Skvortsova further stated that over the past three years of development and testing, the vaccine has demonstrated proven safety—even with repeated, multiple use—and high efficacy.
She emphasized that this marks a new era in individualized cancer treatment.
EnteroMix will initially be used for patients with colorectal cancer, one of the most common and lethal forms of cancer worldwide.
Plans for expanding its application to other cancer types are currently under consideration, pending further trials.
While the early results are promising, medical experts have cautioned that larger-scale clinical trials will be necessary to confirm the vaccine’s efficacy across broader populations and a variety of cancer types.
Nonetheless, the global medical community has acknowledged the announcement as a major step forward in cancer research.
Russia’s decision to offer the vaccine free of charge to trial participants has also drawn international attention, reflecting a commitment to accessible and equitable cancer care.
With EnteroMix, Russia joins a small but growing group of nations advancing mRNA-based therapeutics beyond infectious diseases and into the realm of oncology—building on the platform popularized globally by COVID-19 vaccines.
Further updates are expected as the vaccine enters its next phase of clinical application.
